Suscriptores   Asóciese  
Textos Completos Autorizados
INCIDENCIA, MORTALIDAD Y FACTORES DE RIESGO PARA EL CANCER HEPATICO

v-estudie-lo-mejor.gif
Expertos Invitados




Artículos relacionadosArtículos relacionadosArtículos relacionados
Artículos afines de siicsalud publicados en los últimos 4 meses
EL TRATAMIENTO CON TRASTUZUMAB DERUXTECÁN ES SEGURO EN PACIENTES CON CÁNCER DE MAMA MESTASTÁSICO
ESMO Open 8(4):1-9
Difundido en siicsalud: 19 abr 2024
INCIDENCIA ELEVADA DE RADIODERMATITIS EN MUJERES CON CÁNCER DE MAMA
Anais Brasileiros de Dermatologia 99(1):57-65
Difundido en siicsalud: 2 feb 2024

INCIDENCIA, MORTALIDAD Y FACTORES DE RIESGO PARA EL CANCER HEPATICO

(especial para SIIC © Derechos reservados)
El artículo es una revisión bibliográfica de la epidemiología del cáncer hepático a nivel mundial. Se describe la incidencia y la mortalidad por cáncer hepático según áreas geográficas, así como los factores de riesgo más importantes asociados a este tumor.
ribes9.jpg Autor:
Josepa Ribes Puig
Columnista Experto de SIIC

Institución:
Server d´ Epidemiología i Registre del Càncer, Institut Català d´ Oncología. IDIBELL

Artículos publicados por Josepa Ribes Puig
Coautores
Ramon Clèries* Laura Esteban* F Xavier Bosch* 
Server d´ Epidemiología i Registre del Càncer, Institut Català d´ Oncología. IDIBELL, Barcelona, España*
Recepción del artículo
20 de Julio, 2006 		Aprobación
10 de Agosto, 2006
Primera edición
18 de Diciembre, 2006 		Segunda edición, ampliada y corregida
7 de Junio, 2021

INCIDENCIA, MORTALIDAD Y FACTORES DE RIESGO PARA EL CANCER HEPATICO

Resumen
El cáncer hepático (CH) es una de las neoplasias más frecuentes en el mundo y la primera que puede prevenirse mediante vacunación contra un virus, el de la hepatitis B, y la detección sistemática del virus de la hepatitis C en la sangre y sus derivados. A nivel mundial, en 2002 se diagnosticaron 626 162 casos nuevos de CH. Las áreas geográficas de mayor prevalencia de CH corresponden al sudeste asiático y a algunos países del centro oeste de Africa; las de baja prevalencia, al norte de Europa, Australia, Nueva Zelanda y la población caucásica de América. La incidencia de CH en las áreas de alta prevalencia es 2 a 3 veces mayor que en las de baja prevalencia. Esta variabilidad geográfica sugiere que determinados factores ambientales juegan un papel importante en la etiología de este tumor. El riesgo atribuible de CH en pacientes con infección por los virus de las hepatitis B y C es del 80%. El consumo de alcohol, la ingesta de aflatoxinas y los anticonceptivos orales pueden explicar parte de la variación residual en la incidencia del CH. Otros factores emergentes asociados al CH, como la obesidad y la diabetes, también pueden desempeñar un papel importante en los países desarrollados.

Palabras clave
cáncer hepático, incidencia, mortalidad, virus de la hepatitis B, virus de la hepatitis C


Artículo completo
(castellano)
Extensión:  +/-7.97 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

LIVER CANCER: INCIDENCE, MORTALITY AND RISK FACTORS

Abstract
Liver cancer (LC) is one of the most frequent cancers worldwide and the first that can be prevented by vaccination against hepatitis B virus, and the screening of hepatitis C virus in blood and its derivatives. During the year 2002, it has been estimated that there were 626 162 new cases of LC diagnosed worldwide. The high risk areas for LC are located in Southeastern Asia and in some Central and Western African countries, whereas low risk areas are located in Northern Europe, Australia, New Zealand and the Caucasian population of America. LC incidence in high risk countries is between 2 and 3-fold higher than that of the low-risk countries. This geographical variability suggests that some environmental factors play an important role in the etiology of this tumor. The attributable risk of hepatitis B and C virus is about 80%. Alcohol consumption, aflatoxins and oral contraceptives could partially explain the residual variability of the LC incidence. Other emerging factors associated to LC, such as obesity and diabetes, might also play an important role in developed countries.

Key words
liver cancer, incidence, mortality, hepatitis B virus, hepatitis C virus

Clasificación en siicsalud
Artículos originales > Expertos de Iberoamérica >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Oncología
Relacionadas: Diagnóstico por Imágenes, Diagnóstico por Laboratorio, Epidemiología, Gastroenterología, Medicina Interna



Comprar este artículo
Extensión: 7.97 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Josepa Ribes Puig, Server d'Epidemiología i Registre del Càncer, Institut Català d´ Oncología. IDIBELL, 08907, Gran Via s/n, km 2.7, L'Hospitalet de Llobregat, Barcelona, España
Patrocinio y reconocimiento:
El proyecto ha sido parcialmente financiado con la ayuda del Instituto de Salud de Carlos III del gobierno de España (C03/09, C03/10).
Bibliografía del artículo
1. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents. Vol. VIII. IARC Scientific Publications Nº 155. International Agency for Research on Cancer & International Association of Cancer Registries. Lyon, 2002.
2. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase 2.0 (versión 5). Lyon, 2004.
3. Bosch FX, Ribes J, Díaz M, Clèries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127:S5-S16.
4. Lee HS, Han ChJ, Kim ChY. Predominant etiologic association of hepatitis C virus with hepatocellular carcinoma compared with hepatitis B virus in elderly patients in a hepatitis B-endemic area. Cancer 1993; 72:2564-7.
5. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Seminars Liver Dis 1999; 19(3):271-85.
6. Yu MW, Yang YC, Yang SY y col. Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men. J Natl Cancer Inst 2001; 93(21):1644-51.
7. Yu MW, Chang HC, Chang SC y col. Role of reproductive factors in hepatocellular carcinoma: impact on hepatitis B-and C-related risk. Hepatology 2003; 38(6):1393-1400.
8. Donato F, Tagger A, Gelatti U y col. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002; 155(4):323-31.
9. Coleman MP, Gatta G, Verdecchia A y col. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol 2003; 14(Suppl 5):128-49.
10. Ries LAG, Eisner MP, Kosary CL y col. National Cancer Institute. SEER Cancer Statistics Review, 1975-2002. Disponible en: http://seer.cancer.gov/csr/1975_2002 . Bethesda, 2005.
11. International Classification of Diseases, adapted for use in the United States. 8th revision 1967. Department of Health, Education and Welfare, Public Health Service Publication. Washington, 1693.
12. International Classification of Diseases, 9th Revision, Clinical Modification. Departament of Health and Human Services. Washington, 1979.
13. International statistical classification of diseases and related health problems. 10th Revision. WHO. Geneve, 1992.
14. Hoel DG, Ron E, Carter R, Mabuchi K. Influence of death cerfitifact errors on cancer mortality Trends. J Natl Cancer Inst 1993; 85:1063-8.
15. McGlynn KA, Tsao L, Hsing AW, Devesa SS, Fraumeni jr JF. International trends and patterns of primary liver cancer. Int J Cancer 2001; 94:290-6.
16. Okuda K, Fujimoto I, Hanai A, Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 1987; 47:4967-72.
17. Benhamiche AM, Faivre C, Minello A y col. Time trends and age-period-cohort effects on the incidence of primary liver cancer in a well-defined french population: 1976-1995. J Hepatol 1998; 29:802-6.
18. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979-94. Lancet 1997; 350:1142-3.
19. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340:745-50.
20. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003; 139(10):817-23.
21. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000; 20:1-16.
22. Chang MH, Chen CJ, Lai MS y col. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997; 336:1855-1907.
23. Lee MS, Kim DW, Lee HS y col. Hepatitis B vaccination and reduced risk of primary liver cancer among male adults: a cohort study in Korea. Int J Epidemiol 1998; 27:316-9.
24. Yu SZ, Chen G, Zhi XL y col. Primary liver cancer: natural toxins and prevention in China. J Toxicol Sci 1998; 23 (suppl):143-7.
25. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 2002; 37(6):806-13.
26. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33:1353-7.
27. Hanley AJ, Choi BC, Holowaty EJ. Cancer mortality among Chinese migrants: a review. Int J Epidemiol 1995; 24:255-65.
28. Fang J, Madhavan S, Alderman MH. Cancer mortality of Chinese in New York City 1988-1992. Int J Epidemiol 1996; 25:907-12.
29. Bouchardy C, Parkin DM, Khlat M. Cancer mortality among Chinese and South-East Asian migrants in France. Int J Cancer 1994; 58:638-43.
30. McCredie M, Williams S, Coates M. Cancer mortality in East and Southeast Asian migrants to New South Wales, Australia, 1975-1995. Br J Cancer 1999; 79:1277-82.
31. Grulich AE, Swerdlow AJ, Head J, Marmot MG. Cancer mortality in African and Caribbean migrants to England and Wales. Br J Cancer 1992; 66:905-11.
32. Khlat M, Bouchardy C, Parkin DM. Cancer mortality among near eastern migrants in Australia. Rev Epidemiol Sante Publique 1993; 41:208-17.
33. Rosenblatt KA, Weiss NS, Schwartz SM. Liver cancer in Asian migrants to the United States and their descendants. Cancer Causes Control 1996; 7:345-50.
34. IARC Monographs of the evaluation of carcinogenic risk to humans. Vol. 59. Hepatitis viruses. International Agency for Research on Cancer. Lyon, 1994.
35. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118(12):3030-44.
36. Prince AM, Alcabes P. The risk of development of hepatocellular carcinoma in hepatitis B virus carrier in New York. A preliminary estimate using death-records matching. Hepatology 1982; 2:15-20.
37. Dodd RY, Nath N. Increased risk for lethal forms of liver disease among HBsAg-positive blood donors in the United States. J Virol Methods 1987; 17:81-94.
38. Crook PD, Jones ME, Hall AJ. Mortality of hepatitis B surface antigen-positive blood donors in England and Wales. Int J Epidemiol 2003; 32:118-24.
39. Hall AJ, Winter PD, Wright R. Mortality of hepatitis B positive blood donors in England and Wales. Lancet 1985; 1(8420):91-3.
40. Oshima A, Tsukuma H, Hiyama T, Fujimoto I, Yamamo H, Tanaka M. Follow-up study of HBsAg-positive blood donors with special reference to effect of drinking and smoking on development of liver cancer. Int J Cancer 1984; 34:775-9.
41. Sakuma K, Saitoh N, Kasai M y col. Relative risks of death due to liver disease among Japanese male adults having various statuses for hepatitis B s and e antigen/antibody in serum: a prospective study. Hepatology 1988; 8(6):1642-6.
42. Iijma T, Saitoh N, Nobutomo K, Nambu M, Sakuma K. A prospective cohort study of hepatitis B surface antigen carriers in a working population. Gann 1984; 75:571-3.
43. Tokudome S, Ikeda M, Matsushita K, Maeda Y, Yoshinari M. Hepatocellular carcinoma among female Japanese hepatitis B virus carriers. Hepatogastroenterology 1987; 34: 246-8.
44. Tokudome S, Ikeda M, Matsushita K, Maeda Y, Yoshinari M. Hepatocellular Carcinoma among HBsAg positive blood donors in Fukuoka, Japan. Eur J Cancer Clin Oncol 1988; 2:235-9.
45. Beasley RP, Hwang LY, Lin CC, Chien SC. Hepatocellular carcinoma and hepatitis B virus: A prospective study of 22707 men in Taiwan. Lancet 1981; 2(8256):1129-33.
46. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61:1942-56.
47. Yang HI, Lu SN, Liaw YF y col. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347(3):168-74.
48. Tu JT, Gao RN, Zhang DH, Gu BC. Hepatitis B virus and primary liver cancer on Chongming Island, People's Republic of China. Natl Cancer Inst Monogr 1985; 69:213-5.
49. Yeh FS, Yu MC, Mo ChCh, Luo S, Tong MJ, Henderson BE. Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in Southern Guangxi, China. Cancer Res 1989; 49:2506-9.
50. Ross RK, Yuan JM, Yu MW y col. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992; 339:943-6.
51. Ribes J, Cleries R, Rubio A y col. Cofactors associated with liver disease mortality in an HBsAg-positive Mediterranean cohort: 20 years of follow-up. Int J Cancer 2006; 119(3):687-94.
52. Alter MJ. Epidemiology and prevention of hepatitis B. Semin Liver Dis 2003; 23(1):39-46.
53. Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 127(5 Suppl 2):72-8.
54. Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology 2002; 62(suppl 1):8-17.
55. Okuda K. Chap. 4: Hepatitis C and hepatocellular carcinoma. En: Liver Cancer. Okuda K, Tabor E (eds.). p: 39-50. Churchill Livingstone. New York, 1997.
56. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004; 127(5):1372-80.
57. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000; 160:3227-30.
58. Abdel-Aziz F, Habib M, Mohamed MK y col. Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Hepatology 2000; 32(1):111-5.
59. Frank C, Mohamed MK, Strickland GT y col. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355:887-91.
60. Brechot C, Jaffredo F, Lagorce D y col. Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action. J Hepatol 1998; 29(2):173-83.
61. Bréchot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Bréchot P. Persistent Hepatitis B virus infection in subjects without Hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology 2001; 34:194-203.
62. Hsia CC, Scudamore CH, di Bisceglie AM, Tabor E. Molecular and serological aspects of HBsAg-negative hepatitis B virus infections in North America. J Med Virol 2003; 70(1):20-6.
63. Chu CM, Liaw YF. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol 2005; 43(3):411-17.
64. Kao JH, Chen DS. HBV genotypes and outcome of HBV infection. Hepatology 2005; 41(1):216.
65. Yu MW, Yeh SH, Chen PJ y col. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005; 97(4):265-72.
66. Chu CJ, Keeffe EB, Han SH y col. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology 2003; 125(2):444-51.
67. Bisceglie AM, Carithers RL, Gores GJ. Hepatocellular carcinoma. Hepatology 1998; 28:1161-5.
68. Donato F, Tagger A, Chiesa R y col. Hepatitis B and C virus infections, alcohol drinking, and hepatocellular carcinoma: a case- control study in Italy. Hepatology 1997; 26(3):579-84.
69. Kuper H, Tzonou A, Kaklamani E y col. Tobbaco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 2000; 85(4):498-502.
70. Tzonou A, Trichopoulos D, Kaklamani E y col. Epidemiologic assessment of interactions of hepatitis-C virus with seromarkers of hepatitis-B and -D viruses, cirrhosis and tobacco smoking in hepatocellular carcinoma. Int J Cancer 1991; 49:377-80.
71. Chen ChJ, Liang KY, Chang AS y col. Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma. Hepatalogy 1990; 13:398-406.
72. Hirayama T. A large-scale cohort study on risk factors for primary liver cancer, with special reference to the role of cigarette smoking. Cancer Chemother Pharmacol 1989; 23(suppl):114-7.
73. Yu MW, Hsu FCh, Sheen IS y col. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 1997; 45(11):1039-47.
74. Wang LY, You SL, Lu SN y col. Risk of hepatocellular carcinoma and habits of alcohol drinking, betel quid chewing and cigarette smoking: a cohort of 2416 HBsAg-seropositive and 9421 HBsAg-seronegative male residents in Taiwan. Cancer Causes Control 2003; 14(3):241-50.
75. Chen ZM, Liu BQ, Boreham J, Wu YP, Chen JS, Peto R. Smoking and liver cancer in China: case-control comparison of 36,000 liver cancer deaths vs. 17,000 cirrhosis deaths. Int J Cancer 2003; 107(1):106-12.
76. Chang CC, Yu MW, Lu CF, Yang CS, Chen CJ. A nested case-control study on association between Hepatitis C virus antibodies and Primary liver cancer in a cohort of 9,775 men in Taiwan. J Med Virol 1994; 43:276-80.
77. Mori M, Hara M, Wada I, Yamamoto K, Honda M, Naramoto J. Prospective study of hepatitis B and C viral infections, cigarette smoking, alcohol consumption and other factors associated with hepatocellular carcinoma risk in Japan. Am J Epidemiol 2000; 151:131-9.
78. Tsukuma H, Hiyama T, Tanaka S y col. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328:1797-1801.
79. IARC Monographs on the evaluation of carcinogenic risks to humans, Vol. 83. Tobacco Smoke and Involuntary Smoking. IARC Press, Lyon, 2003.
80. Sun Z, Lu P, Gail MH y col. Increased risk of hepatocellular carcinoma in male Hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1. Hepatology 1999; 30:379-83.
81. Kew MC. Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Int 22003; 3(6):405-9.
82. Qian GS, Ross RK, Yu MC y col. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev 1994; 3(1):3-10.
83. Ming L, Thorgeirsson SS, Gail MH y col. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology 2002; 36(5):1214-20.
84. Yu MW, Tong MJ, Govindarajan S, Henderson BE. Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-asians of Los Angeles county, California. J Natl Cancer Inst 1991; 83:1820-6.
85. La Vecchia C, Tavani A, Franceschi S, Parazzini F. Oral contraceptives and cancer. Drug Safety 1996; 14:260-72.
86. The Collaborative MILTS Project Team. Oral contraceptives and liver cancer. Results of the Multicentre International Liver Tumor Study (MILTS). Contraception 1997; 56(5):275-84.
87. Kew MC, Song E, Mohammed A. Contraceptive steroids as a risk factor for hepatocellular carcinoma: a case control study in south African black. Hepatology 1990; 11:298-302.
88. Mant JWF, Vessey MP. Trends in mortality from primary liver cancer in England and Wales 1975-92: influence of oral contraceptives. Br J Cancer 1995; 72:800-3.
89. Waetjen LE, Grimes DA. Oral contraceptives and primary liver cancer: temporal trends in three countries. Obstet Gynecol 1996; 88:945-9.
90. Beral V, Hermon C, Kay C, Hannaford P, Darby S, Reeves G. Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46 000 women from Royal College of General Practitioners' oral contraception study. BMJ 1999; 18:96-100.
91. Kurozawa Y, Ogimoto I, Shibata A y col. Coffee and risk of death from hepatocellular carcinoma in a large cohort study in Japan. Br J Cancer 2005; 93(5):607-10.
92. Gelatti U, Covolo L, Franceschini M y col. Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: a case-control study. J Hepatol 2005; 42(4):528-34.
93. Inoue M, Yoshimi I, Sobue T, Tsugane S. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst 2005; 97(4):293-300.
94. Sharp GB, Lagarde F, Mizuno T y col. Relationship of hepatocellular carcinoma to soya food consumption: a cohort-based, case-control study in Japan. Int J Cancer 2005; 115(2):290-5.
95. Casanovas-Taltavull T, Ribes J, Berrozpe A y col. Patient with hepatocellular carcinoma related to prior acute arsenic intoxication and occult HBV: epidemiological, clinical and therapeutic results after 14 years of follow-up. World J Gastroenterol 2006; 12(12):1972-4.
96. Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 2004; 127(5 Suppl 2):79-86.
97. Yu MW, Hsieh HH, Pan WH, Yang CS, Chen Ch J. Vegetable consumption, serum retinol level, and risk of hepatocellular carcinoma. Cancer Res 1995; 55:1301-5.
98. El Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am J Gastroenterol 2001; 96(8):2462-7.
99. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005; 54(4):533-9.
100. Hassan MM, Hwang LY, Hatten CJ, Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002; 36(5):1206-13.
101. Caldwell SH, Crespo DM, Kang HS, Al Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology 2004; 127(5 Suppl 2):97-103.
102. Gonzalez L, Blanc JF, Cunha A y col. Obesity as a risk factor for hepatocellular carcinoma in a noncirrhotic patient. Semin Liver Dis 2004; 24(4):415-9.
103. Montesano R. Hepatitis B immunization and hepatocellular carcinoma: The Gambia Hepatitis Intervention Study. J Med Virol 2002; 67(3):444-6.
104. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus Infection: Epidemiology and Vaccination. Epidemiol Rev 2006 (en prensa).
105. Hsu HM, Chen DS, Chuang CH y col. Efficacy of a mass hepatitis B vaccination program in Taiwan. JAMA 1988; 260:2231-5.
106. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board. J Viral Hepat 1999; 6(1):35-47.
107. Alter MJ. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 2003; 39:64-9.
108. Kiyosawa K, Tanaka E, Sodeyama T y col. Transmission of hepatitis C in an isolated area in Japan: community-acquired infection. The South Kiso Hepatitis Study Group. Gastroenterology 1994; 106:1596-1602.
109. Bosch FX, Ribes J, Clèries R, Díaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005; 9(2):191-211.
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
Artículos relacionadosMás relacionadosAtículos relacionados
ua31618
Acerca de SIIC   Estructura de SIIC   Fuentes informativas  

Sociedad Iberoamericana de Información Científica

Copyright siicsalud© 1997-2024 ISSN siicsalud: 1667-9008
ua31517